News
Category: DIAN-TU Announcement
Update on the DIAN-TU-001 Trial with E2814 and Investigational Lecanemab (Eisai Co., Ltd)
The statement below is in response to the 28 September 2022 announcement found on Eisai’s website. Eisai Co., Ltd. (Headquarters:...
New Alzheimer’s prevention trial in young people
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE NEWS RELEASE - DEC 20 2021
$11.5 million commitment supports new Alzheimer’s prevention clinical trial
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE NEWS RELEASE - DEC 20 2021
International Alzheimer’s clinical trial to test two drugs in combination
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE NEWS RELEASE - NOV 8 2021
International Alzheimer’s clinical trial to test tau drugs
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE NEWS RELEASE - MAR 15 2021 Gantenerumab improved markers of disease in rare, inherited form of Alzheimer’s disease
Further analysis of data from an international trial of two investigational drugs in people in the early stages of a...
Investigational drugs didn’t slow memory loss, cognitive decline in rare, inherited Alzheimer’s, initial analysis indicates
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE NEWS RELEASE - FEB 10 2020
Major Alzheimer’s study to open 5 new Latin American sites
Washington University School of Medicine news release - Nov 20 2019 Update on the DIAN-TU-001 TRIAL
Update on the DIAN-TU-001 TRIAL: Janssen BACE Inhibitor (JNJ-54861911/atabecestat) DRUG ARM DISCONTINUATION The statement below is an update to the...
DIAN-TU Trial Interim Analysis
Notice to DIAN-TU Investigational Sites and Participants RE: DIAN-TU-001 INTERIM ANALYSIS April 25, 2018 DIAN-TU Site Leaders and Participants, The...